Vascepa monopolisation claims survive motion to dismiss

Davide Mamone

02 March 2023

A New Jersey federal judge has refused to throw out a lawsuit alleging that Amarin Pharma prevented generic competition for the cholesterol-lowering drug Vascepa.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Davide Mamone

View full biography

Author | News reporter, GCR USA

[email protected]

Tipline

Waiting for the smoke to clear: The Tipline for 2 June 2023
The Altria/Juul saga is officially over. Or is it? The Marlboro maker says it received “antitrust clearance” for its purchase of e-cigarette startup NJOY this week, but the Federal Trade Commission is still litigating against the company’s abandoned investment in Juul – a case Altria won before the FTC’s administrative law judge last year. The agency insisted that staff’s appeal must go on, but the ruling due four weeks ago from its three Democratic …
The doing it Alone Star State: The Tipline for 1 June 2023
To AI or not to AI: The Tipline for 31 May 2023

Vascepa monopolisation claims survive motion to dismiss

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Davide Mamone